WO2000007025A3 - Methods for predicting drug response, in particular igf-i - Google Patents

Methods for predicting drug response, in particular igf-i Download PDF

Info

Publication number
WO2000007025A3
WO2000007025A3 PCT/US1999/017103 US9917103W WO0007025A3 WO 2000007025 A3 WO2000007025 A3 WO 2000007025A3 US 9917103 W US9917103 W US 9917103W WO 0007025 A3 WO0007025 A3 WO 0007025A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
drug response
predicting drug
subject
particular igf
Prior art date
Application number
PCT/US1999/017103
Other languages
French (fr)
Other versions
WO2000007025A2 (en
Inventor
Desmond Mascarenhas
Original Assignee
Celtrix Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celtrix Pharma filed Critical Celtrix Pharma
Priority to AU53240/99A priority Critical patent/AU5324099A/en
Publication of WO2000007025A2 publication Critical patent/WO2000007025A2/en
Publication of WO2000007025A3 publication Critical patent/WO2000007025A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4745—Insulin-like growth factor binding protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/65—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Abstract

Methods are provided for predicting the response of a subject to a drug or treatment regimen. The predictive measurement is used with biochemical parameters obtained from a subject to predict whether that subject will respond to the particular drug or treatment regimen. Predictive methods may also be used to determine the equivalence of different dosages of a drug.
PCT/US1999/017103 1998-07-27 1999-07-27 Methods for predicting drug response, in particular igf-i WO2000007025A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU53240/99A AU5324099A (en) 1998-07-27 1999-07-27 Methods for predicting drug response

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/123,050 1998-07-27
US09/123,050 US6087090A (en) 1997-02-25 1998-07-27 Methods for predicting drug response

Publications (2)

Publication Number Publication Date
WO2000007025A2 WO2000007025A2 (en) 2000-02-10
WO2000007025A3 true WO2000007025A3 (en) 2000-11-23

Family

ID=22406450

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/017103 WO2000007025A2 (en) 1998-07-27 1999-07-27 Methods for predicting drug response, in particular igf-i

Country Status (3)

Country Link
US (1) US6087090A (en)
AU (1) AU5324099A (en)
WO (1) WO2000007025A2 (en)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2330219A3 (en) * 2000-04-14 2011-11-23 Metabolon, Inc. Method for drug discovery, disease treatment and diagnosis using metabolomics
US7329489B2 (en) * 2000-04-14 2008-02-12 Matabolon, Inc. Methods for drug discovery, disease treatment, and diagnosis using metabolomics
US20050244422A1 (en) * 2004-04-16 2005-11-03 Desmond Mascarenhas Methods for delivering MBD peptide-linked agent into cells under conditions of cellular stress
US20040018501A1 (en) * 2001-11-21 2004-01-29 Keith Allen Methods and systems for analyzing complex biological systems
US7288257B2 (en) * 2002-05-23 2007-10-30 Michael Powell Diagnosis and treatment of human dormancy syndrome
US7485298B2 (en) * 2002-05-23 2009-02-03 Michael Powell Diagnosis and treatment of human dormancy-related sequellae
US20060003391A1 (en) * 2003-08-11 2006-01-05 Ring Brian Z Reagents and methods for use in cancer diagnosis, classification and therapy
US20050112622A1 (en) 2003-08-11 2005-05-26 Ring Brian Z. Reagents and methods for use in cancer diagnosis, classification and therapy
US20080131916A1 (en) * 2004-08-10 2008-06-05 Ring Brian Z Reagents and Methods For Use In Cancer Diagnosis, Classification and Therapy
US20060059017A1 (en) * 2004-08-27 2006-03-16 The Trustees Of Boston University Method and system for performing post-marketing surveillance of drugs using pharmacy-based cohorts
US7504225B2 (en) * 2005-05-12 2009-03-17 Applied Genomics, Inc. Reagents and methods for use in cancer diagnosis, classification and therapy
AU2006311538A1 (en) * 2005-11-09 2007-05-18 Ontherix, Inc. Metal-binding therapeutic peptides
US20080039393A1 (en) * 2005-11-09 2008-02-14 Desmond Mascarenhas Metal-binding therapeutic peptides
US7611893B2 (en) 2005-11-09 2009-11-03 Ontherix, Inc. Metal-binding therapeutic peptides
US7662624B2 (en) * 2005-11-09 2010-02-16 Ontherix, Inc. Metal-binding therapeutic peptides
US20080103746A1 (en) 2005-11-30 2008-05-01 Searete Llc, A Limited Liability Corporation Systems and methods for pathogen detection and response
US7974856B2 (en) 2005-11-30 2011-07-05 The Invention Science Fund I, Llc Computational systems and methods related to nutraceuticals
US8297028B2 (en) 2006-06-14 2012-10-30 The Invention Science Fund I, Llc Individualized pharmaceutical selection and packaging
US8340944B2 (en) 2005-11-30 2012-12-25 The Invention Science Fund I, Llc Computational and/or control systems and methods related to nutraceutical agent selection and dosing
US8000981B2 (en) 2005-11-30 2011-08-16 The Invention Science Fund I, Llc Methods and systems related to receiving nutraceutical associated information
US7827042B2 (en) 2005-11-30 2010-11-02 The Invention Science Fund I, Inc Methods and systems related to transmission of nutraceutical associated information
US10296720B2 (en) 2005-11-30 2019-05-21 Gearbox Llc Computational systems and methods related to nutraceuticals
US7927787B2 (en) 2006-06-28 2011-04-19 The Invention Science Fund I, Llc Methods and systems for analysis of nutraceutical associated components
US8849577B2 (en) * 2006-09-15 2014-09-30 Metabolon, Inc. Methods of identifying biochemical pathways
US20080167571A1 (en) * 2006-12-19 2008-07-10 Alan Gevins Determination of treatment results prior to treatment or after few treatment events
US8065240B2 (en) 2007-10-31 2011-11-22 The Invention Science Fund I Computational user-health testing responsive to a user interaction with advertiser-configured content
US20080242951A1 (en) * 2007-03-30 2008-10-02 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Effective low-profile health monitoring or the like
US20090132275A1 (en) * 2007-11-19 2009-05-21 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Determining a demographic characteristic of a user based on computational user-health testing
US20080243543A1 (en) * 2007-03-30 2008-10-02 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Effective response protocols for health monitoring or the like
US20080242948A1 (en) * 2007-03-30 2008-10-02 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Effective low-profile health monitoring or the like
US20090112621A1 (en) * 2007-10-30 2009-04-30 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational user-health testing responsive to a user interaction with advertiser-configured content
US20090119154A1 (en) * 2007-11-07 2009-05-07 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Determining a demographic characteristic based on computational user-health testing of a user interaction with advertiser-specified content
US20080242952A1 (en) * 2007-03-30 2008-10-02 Searete Llc, A Limited Liablity Corporation Of The State Of Delaware Effective response protocols for health monitoring or the like
US20090112616A1 (en) * 2007-10-30 2009-04-30 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Polling for interest in computational user-health test output
US20080287821A1 (en) * 2007-03-30 2008-11-20 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational user-health testing
US20080242950A1 (en) * 2007-03-30 2008-10-02 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational user-health testing
US20090005654A1 (en) * 2007-03-30 2009-01-01 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational user-health testing
US20090024050A1 (en) * 2007-03-30 2009-01-22 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational user-health testing
US20080319276A1 (en) * 2007-03-30 2008-12-25 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational user-health testing
US8536135B2 (en) * 2008-03-19 2013-09-17 Ontherix, Inc. Adaptive biochemical signatures
WO2009157945A1 (en) * 2008-06-27 2009-12-30 Alan Gevins Determination of treatment results prior to treatment or after few treatment events
US20100292545A1 (en) * 2009-05-14 2010-11-18 Advanced Brain Monitoring, Inc. Interactive psychophysiological profiler method and system
US20160246919A1 (en) * 2013-10-08 2016-08-25 The Regents Of The University Of California Predictive optimization of network system response
AU2015243857A1 (en) 2014-04-08 2016-10-20 Metabolon, Inc. Small molecule biochemical profiling of individual subjects for disease diagnosis and health assessment

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5407927A (en) * 1993-04-16 1995-04-18 The Regents Of The University Of California Treatment of mild depression and restoration of IGF-I levels in aging by dehydroepiandrosterone
US5593844A (en) * 1990-11-19 1997-01-14 Genentech, Inc. Ligand-mediated immunofunctional hormone binding protein assay method
WO1997038709A1 (en) * 1996-04-12 1997-10-23 Pharmacia & Upjohn Ab Use of growth hormone
WO1998037423A1 (en) * 1997-02-25 1998-08-27 Celtrix Pharmaceuticals, Inc. Method for predicting drug response, in particular igf-i

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4880014A (en) * 1987-08-14 1989-11-14 Zarowitz Barbara J Method for determining therapeutic drug dosage using bioelectrical resistance and reactance measurements
US5209920A (en) * 1988-11-30 1993-05-11 The United States Of America As Represented By The United States Department Of Health And Human Services Evaluative means for detecting inflammatory reactivity
EP0563654A1 (en) * 1992-03-18 1993-10-06 Hoechst-Roussel Pharmaceuticals Incorporated Risk determination for drug treatment
US5370135A (en) * 1993-10-13 1994-12-06 Biex, Inc. Use of estriol measurement to monitor tocolytic therapy
SE9501782D0 (en) * 1995-05-12 1995-05-12 Landstinget I Oestergoetland Method of predicting the therapeutic response of a drug against a malignant tumor

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5593844A (en) * 1990-11-19 1997-01-14 Genentech, Inc. Ligand-mediated immunofunctional hormone binding protein assay method
US5407927A (en) * 1993-04-16 1995-04-18 The Regents Of The University Of California Treatment of mild depression and restoration of IGF-I levels in aging by dehydroepiandrosterone
WO1997038709A1 (en) * 1996-04-12 1997-10-23 Pharmacia & Upjohn Ab Use of growth hormone
WO1998037423A1 (en) * 1997-02-25 1998-08-27 Celtrix Pharmaceuticals, Inc. Method for predicting drug response, in particular igf-i

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ROELEN, CORNE A. M. ET AL: "High-affinity growth hormone (GH)-binding protein (GHBP), body fat-- mass, and insulin - like growth factor-binding protein- predict the GHBP response to GH therapy in adult GH deficiency syndrome.", METABOLISM CLINICAL AND EXPERIMENTAL, (MARCH, 1999) VOL. 48, NO. 3, PP. 314-318., XP000892210 *

Also Published As

Publication number Publication date
WO2000007025A2 (en) 2000-02-10
AU5324099A (en) 2000-02-21
US6087090A (en) 2000-07-11

Similar Documents

Publication Publication Date Title
WO2000007025A3 (en) Methods for predicting drug response, in particular igf-i
WO2000001845A3 (en) Method for early diagnosis of carcinomas
MX9704363A (en) Device for performing one or more competitive immunoassays.
IS6333A (en) DNA-ordering process
GR3036073T3 (en) Analytical test apparatus with on board negative and positive control.
AU2849300A (en) Methods and assay kits for detecting mononuclear cell phenotype
NO178047C (en) Enzyme-based, immunological analysis for an antigen as well as solid phase for use in the assay
CA2295905A1 (en) Urine adulteration test method
IL143098A0 (en) A method of detecting the presence of an analyte in a biological sample
WO2003087760A3 (en) Methods for detecting bcr-abl signaling activity in tissues using phospho- specific antibodies
WO2004054885A3 (en) Method for replacing used reaction cuvettes in an automatic analyzer depending upon next scheduled assay
MY138198A (en) Stage predicting system
NO964015L (en) Method for detecting calpain activation and identifying calpain inhibitors
EP0964249A3 (en) Method for measuring LDL-cholesterol
IT1261006B (en) WASHING MACHINE WITH CONSUMPTION OF CONTROLLED DETERGENT, AND RELATED CONTROL METHOD.
SE0004875D0 (en) Method of acquiring satellite
WO2004015420A8 (en) Method for diagnosing multiple sclerosis
AU2000264217A1 (en) Method for detecting serum and for determining the quality thereof, and corresponding devices
WO2005048108A3 (en) System, method, and computer program product for testing program code
DE69732034D1 (en) ASSAY METHOD
NO974000D0 (en) Methods and compounds for detecting analytes, by means of residue measurements, and using such compounds
EP1712918A4 (en) Method of detecting thrombosis through measuring of von willebrand factor splitting enzyme
EP1568995A4 (en) New probe plate based on antigen-antibody reaction and reagent kit and method using the probe plate
DE69738503D1 (en) THE DETECTION OF OXIDIZED AND MDA-MODIFIED LIPOPROTEINS OF LESS DENSITY
AU2003242106A8 (en) Detection kit, assay plate to be used therein, detection method, evaluation method, polyclonal antibody of frog vitellogenin and procss for producing the same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

122 Ep: pct application non-entry in european phase